Vol. 5 No. 6 (2025)
Reimbursement Reviews

Zilucoplan (Zilbrysq)

decorative image of the issue cover

Published June 20, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses zilucoplan (Zilbrysq), solution for injection (16.6 mg/0.416 mL, 23.0 mg/0.574 mL, and 32.4 mg/0.81 mL [each corresponding to 40 mg/mL] in single-dose prefilled syringes) for subcutaneous (SC) use.
  • Indication: For the treatment of generalized myasthenia gravis (gMG) in adult patients who are acetylcholine receptor (AChR) antibody-positive. Patients continued to receive standard therapy throughout the pivotal trial.